TACSTD2 and gastric cancer: Sacituzumab govitecan, the first-in-class anti-Trop2 antibody-drug conjugate (ADC), was approved by the US FDA in 2020 for the third-line treatment of metastatic triple-negative breast cancer (TNBC).606 Clinical trials are underway to expand the use of sacituzumab govitecan in multiple solid tumors, including GC.